Recent advances in the management of colorectal polyps

Beauchamp, Daniel; Peeler, Mark O.; DuBois, Raymond N.

doi:10.1097/00001574-199601000-00004

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer is the second most common fatal malignancy in the western world, with approximately 150,000 new cases accounting for 55,000 deaths in the United States every year (Beauchamp et al, 1996). It is estimated that 90% of these cancers arise from adenomatous polyps.…”

Section: Introductionmentioning

confidence: 99%

TGF-? and colorectal carcinogenesis

Roman

Saha

Beauchamp

2001

Microsc. Res. Tech.

View full text Add to dashboard Cite

There is substantial evidence to support the contention that the Smad portion of the TGF‐β signal transduction pathway provides an important tumor‐suppressor function. Mutational loss of function of Smad pathway members have been associated with the development of human cancers and appear to be causative in selected rodent carcinogenesis models. TGF‐β also has multiple other actions that appear to be independent of the growth‐inhibitory/tumor suppressor effects. The predominant effect of TGF‐β appears to be dependent on the context of the responding cell. Once transformation has occurred, TGF‐β effects may be detrimental and may actually promote tumor cell survival, invasion, and metastasis. Recent work suggests that these effects may involve TGF‐β regulation of COX‐2 and other pathways that may contribute to tumor cell aggressiveness. In gaining a better understanding of the mechanisms by which TGF‐β may promote tumor progression, it is likely that new therapeutic strategies may be developed that preserve tumor‐suppressor function of TGF‐β while inhibiting the tumor‐promoting effects. Microsc. Res. Tech. 52:450–457, 2001. © 2001 Wiley‐Liss, Inc.

show abstract

Section: Introductionmentioning

confidence: 99%

TGF-? and colorectal carcinogenesis

Roman

Saha

Beauchamp

2001

Microsc. Res. Tech.

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is the second most common fatal malignancy in the Western world, with more than 150,000 new cases accounting for 55,000 deaths in the United States every year [1].…”

mentioning

confidence: 99%

New Strategies for Colorectal Cancer Prevention and Treatment

Saha

Roman²,

Beauchamp³

2002

World j. surg.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the second most common fatal malignancy in the Western world, with more than 150,000 new cases accounting for 55,000 deaths in the United States every year. Surgical resection is an effective treatment for localized disease, achieving a 5-year survival rate of 90%; but chemotherapy and other novel treatments for metastatic disease remain ineffective. There have been significant efforts to identify risk factors associated with the development of CRC and to explore potential preventive therapies. Both genetic and epigenetic factors contribute to the development of colorectal cancer. Specific genetic changes in proto-oncogenes, tumor suppressor genes, and DNA mismatch repair genes have led to a genetic model of CRC. Cooperative genetic aberrations involving APC (adenomatous polyposis coli), beta-catenine, K-ras, and p53 are involved in the multistep adenoma-carcinoma sequence of CRC. Emerging data have implicated cyclooxygenase-2 (COX-2) and prostanoid production in the pathogenesis of colorectal carcinoma. Several reports indicate a close relation between the intake of nonsteroidal antiinflammatory drugs (NSAIDs) and a decreased risk for developing colorectal cancer. Epidemiologic studies indicate a 40% to 50% reduction in mortality due to colorectal cancer in individuals taking NSAIDs (e.g., aspirin). Epigenetic factors including age, diet, angiogenesis, and immune responses also appear to contribute to the development of CRC. Combining knowledge of the genetic and epigenetic events implicated in this disease may allow a broader understanding of the pathogenesis of CRC. These developments may yield benefits in earlier detection and in the design of better antitumor interventions.

show abstract